Inhibrx: 'Strong Buy' Maintained With Ozekibart Action Date On The Horizon And Study Win With INBRX-106

Inhibrx Biosciences retains a Strong Buy rating following FDA acceptance of ozekibart's BLA for unresectable/metastatic chondrosarcoma, with a PDUFA action date of April 14, 2027. The company also reported positive interim ozekibart data in third-/fourth-line colorectal cancer and strong Phase 2 results for INBRX-106 combined with KEYTRUDA in head and neck squamous cell carcinoma. The clinical and regulatory milestones strengthen the company's oncology pipeline outlook.

Analysis

INBX's valuation is likely to become increasingly dependent on probability-of-approval assumptions rather than near-term earnings, creating a long-duration biotech setup with substantial discount-rate sensitivity. The regulatory milestone can support a higher floor under the lead asset's risk-adjusted NPV, but the April 2027 decision horizon means the stock still requires durable financing capacity and clean execution across intervening clinical updates. Positive single-arm or interim oncology results should not be treated as confirmatory until durability, survival maturity, safety, and enrollment representativeness are disclosed against meaningful historical benchmarks.

The more actionable near-term catalyst is not the eventual decision date but protocol, enrollment, and data-readout cadence over the next 3-12 months. INBRX-106's combination potential could expand strategic value if efficacy differentiates from PD-1-based standards without incremental immune toxicity; however, Merck (MRK) is too large for any program-level read-through to matter financially. Consensus may underappreciate that a rare-tumor filing can attract takeover interest from oncology-focused acquirers, while simultaneously overpricing the value of earlier-line expansion before randomized evidence establishes a commercializable benefit.

The principal downside is a financing and valuation-reset cycle: if follow-on studies require more capital than the market expects, dilution can outweigh incremental clinical de-risking. A weaker-than-expected durability update, serious adverse-event signal, FDA request for additional data, or cash runway falling below roughly 12 months would challenge the thesis well before the regulatory endpoint.

Key Decisions for Investors

• Do not chase a broad post-milestone move in INBX; build only on pullbacks or after disclosure of duration-of-response, overall-survival follow-up, and cash runway. Size as a 6-18 month catalyst position, not a 2027 approval trade, given the absence of near-term revenue support.
• For a long INBX position, hedge sector beta with a partial short in XBI rather than a single-name oncology short. This isolates asset-specific clinical/regulatory upside while reducing exposure to biotech funding-rate and risk-appetite shocks over the next 3-6 months.
• Set a pre-defined thesis review at the next material ozekibart or INBRX-106 update: add only if durability and safety improve the probability-weighted commercial case; reduce if efficacy is limited to early response rates without mature follow-up. A material capital raise at a steep discount or runway below 12 months is a risk-control trigger.
• Monitor strategic-interest signals rather than assuming an acquisition premium: partnering, trial expansion funded by a larger oncology company, or formal manufacturing/commercial preparations would be more credible evidence of external validation. Without these, treat takeover optionality as unpriced upside rather than a core underwriting assumption.